Olverembatinib, a novel BCR-ABL tyrosine kinase inhibitor, exhibits anti-tumor activity and synergizes with gemcitabine in pancreatic ductal adenocarcinoma
A drug approved for leukemia shows potential activity in hard-to-treat pancreatic cancer patients who've exhausted other options.
Olverembatinib (a multi-target TKI approved for CML/ALL in China) demonstrated potent anti-tumor effects in PDAC preclinical models and showed synergy with gemcitabine via SRC/JAK1-STAT1 mechanisms. Critically, clinical case data showed promising efficacy in advanced PDAC patients who had failed multiple prior therapy lines including gemcitabine, suggesting a repurposing opportunity for one of oncology's hardest-to-treat cancers.
What the study was
- Study design
- Preclinical + early clinical case series
- Population
- PDAC patients and cell/mouse models
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- NPJ Precis Oncol
Why it surfaced
PDAC has very high unmet need and extremely limited treatment options; olverembatinib is an approved TKI being repurposed with mechanistic rationale; clinical patient data included despite primarily preclinical study. NOVEL_TREATMENT flag triggers HIGH.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.